Arisvia Sukma Hariftiyani

Arisvia Sukma Hariftiyani

Auto-generated profile, based on publicly available information

Arisvia Sukma Hariftiyani

Faculty of Medicine Universitas Airlangga Surabaya Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2021 in Journal of Basic and Clinical Physiology and Pharmacology
Verified
Journal Article
Closed access
SDSaskia R. Desita
Saskia R. Desita
AHArisvia S. Hariftyani
Arisvia S. Hariftyani
AJAyik R. Jannah
Ayik R. Jannah
ASAssyadila K. Setyobudi
Assyadila K. Setyobudi
YOYudi Her Oktaviono
Yudi Her Oktaviono
Coronary artery disease (CAD) is a disease characterized by atherosclerosis formation which causes sudden cardiac death. The prevalence of CAD is expected to increase by 2030. Atherosclerosis started from accumulation of LDL in the blood vessels, followed by endothelial cell activation and dysfunction. PCSK9 is a gene that plays an important role in the creation of atherosclerotic plaque through induced degradation of LDLRs. Inhibition of PCSK9 gene resulted in a decrease of LDLRs degradation and reduction in LDL-C levels. LRP6, as well as its mutation, is a coreceptor that contributes to atherosclerosis through the canonical Wnt/β-catenin pathway. By employing EMPs mediated miRNA-126, third-generation antisense against miR-494-3p (3 GA-494), and recombinant Wnt mouse Wnt3a (rmWnt3a), the inhibition of LRP6 could reduce VSMCs proliferation, enhancing anti-inflammatory macrophages, and diminished bioactive lipids component, respectively. Those mechanisms lead to the stabilization and reduction of atherosclerosis plaques.

10 September 2022 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
PDF file
MAMeity Ardiana
Meity Ardiana
PHPrimasitha Maharany Harsoyo
Primasitha Maharany Harsoyo
HHHanestya Oky Hermawan
Hanestya Oky Hermawan
ISInna Maya Sufiyah
Inna Maya Sufiyah
DFDwika Rasyid Firmanda
Dwika Rasyid Firmanda
FTFita Triastuti
Fita Triastuti
Background Police officers are known for fieldwork shifts, psychological stress, and prolonged physical activity that are associated with cardiovascular disease (CVD). We aim to determine the differences in CVD risks factor and Atherogenic Index of Plasma (AIP) profiles as a predictor of cardiac events between police officers and civilians in a developing country as an evaluation and strategic preventive measure for CVD. Methods 978 participants were enrolled as subjects in this cross-sectional study. Data used were obtained during medical check-ups using complete physical and laboratory examinations including blood pressure, body mass index (BMI), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, fasting blood sugar, and AIP between 2019 and 2020 at Bhayangkara State Police Hospital Surabaya. Mann-Whitney U test was performed using IBM SPSS version 25. Results There are significant differences in systolic (p = 0.000) and diastolic blood pressure (p = 0.003), triglycerides (p = 0.000), LDL-C (p = 0.006), total cholesterol (p = 0.000), fasting blood glucose (p = 0.001), and the AIP (p = 0.000) between the police and civilian groups, with the latter showing a tendency of having higher rates. Conclusions CVD risk was found in both groups. Nevertheless, police officers have higher AIP and overall CVD risk compared to civilians, creating a necessity for aggressive CVD prevention strategies within the population.

28 October 2025 in Indonesian Journal of Biomedicine and Clinical Sciences
Verified
Journal Article
Closed access
ASAssyadilla Kirana Setyobudi
Assyadilla Kirana Setyobudi
VYValentino Ryu Yudianto
Valentino Ryu Yudianto
AHArisvia Sukma Hariftyani
Arisvia Sukma Hariftyani
GSGatot Soegiarto
Gatot Soegiarto
Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, involve chronic inflammation of the digestive tract. The incidence of IBD has been increasing globally, posing a growing burden despite advancements in treatment. Novel therapies targeting adhesion molecules such as MAdCAM-1 show promise by specifically inhibiting lymphocyte infiltration into the gut, potentially offering safer and more effective treatment options. This meta-analysis and systematic review were conducted to provide efficacy and safety analysis of ontamalimab for IBD treatment. Dose-response (DRMA), network (NMA), and random effect meta-analysis were conducted to extract clinical response, clinical remission, biomarker change, and adverse events of ontamalimab. Studies were retrieved from PubMed, Cochrane, and EMBASE to describe the pooled risk ratio (RR) and heterogeneity was determined if I2 >50%. RoB2 tool and ROBINS-I were used to assess risk of bias in RCT and clinical trial studies, respectively. The result was considered significant if p<0.05. A total of 670 studies were screened, resulting in 8 multicentre studies. There were significant differences in clinical response (RR: 1.39; 95%CI: 1.12–1.73; p = 0.003; I2= 35%), clinical remission (RR: 1.72; 95%CI: 1.17–2.53; p=0.006; I2= 26%), mean change of FC (RR: 624.29; 95%CI: 543.28-705.29; p<0.001; I2= 0%), mean change of CRP serum (RR: 9.71; 95%CI: 7.12–12.3; p<0.001), and mean MAdCAM-1 serum level (RR: 235.57; 95%CI: 203.80–267.33; p <0.001) between ontamalimab 75 mg and placebo after 12 wk of treatment. Meanwhile, adverse events from both groups were similar to those observed in patients treated with either placebo or ontamalimab. This study concluded that ontamalimab 75mg demonstrated significant efficacy in treating IBD, achieving superior outcomes in clinical response and clinical remission compared to placebo. Importantly, no cases of PML and significant adverse events were detected, indicating a favorable safety profile relative to other anti-MAdCAM-1 therapies.